 In this study, the investigators examine using a combination of two types of HLA-A2402 or HLA-A0201-restricted epitope peptides, which were derived from VEGF-R1 and VEGF-R2 the safety, immunogenicity, and antitumor effect of vaccine treatment for advanced solid tumor patients who are refractory to standard therapy. 